TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01139164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen A
Description: Chronic Lymphocytic Leukemia/ Chronic Prolymphocytic Leukemia, Multiple Myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen B
Description: Other malignancies not addressed in A or C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen C
Description: B-Cell Lymphomas
Study: NCT02280629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-02
Description: LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: LT-02 PLACEBO twice daily AND mesalamine 500mg three-times daily
Study: NCT02714309

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: 20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed macronutrient breakfast meal
Description: A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kilojoules (kJ); 468 kcal total)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed macronutrient breakfast meal
Description: A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kilojoules (kJ); 468 kcal total)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed macronutrient breakfast meal
Description: A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kilojoules (kJ); 468 kcal total)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum lunch meal
Description: A mixed-macronutrient lunch served to all participants ad libitum. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum lunch meal
Description: A mixed-macronutrient lunch served to all participants ad libitum. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum lunch meal
Description: A mixed-macronutrient lunch served to all participants ad libitum. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low/moderate intensity exercise
Description: A 30 minute bout of treadmill walking is performed on a motorised treadmill at a low/moderate intensity (55% estimated VO2max)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low/moderate intensity exercise
Description: A 30 minute bout of treadmill walking is performed on a motorised treadmill at a low/moderate intensity (55% estimated VO2max)
Study: NCT00797108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulopenem and PF-03709270
Description: Sulopenem - 600 mg infused over 1 hour, single loading dose and switch to oral PF-03709270 - 1000 mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulopenem and PF-03709270
Description: Sulopenem - 600 mg infused over 1 hour twice daily for a minimum of 2 days and switch to oral PF-03709270 - 1000 mg twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone and amoxicillin/clavulanate
Description: IV ceftriaxone (2g) infused over 30 minutes QD (once daily) for minimum of 2 days Step down oral amoxicillin/clavulanate potassium suspension (400 mg/5 ml) BID (every 12 hours)
Study: NCT03194464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: submaximal exercise (grip)
Description: participants perform repeated gripping with visual feedback to task failure
Study: NCT02538445

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Memorization of the verbs by miming the action
Description: The participant reads aloud the verbs that appear on the screen, by performing the corresponding action verb.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memorization of the verbs by miming the action
Description: The participant reads aloud the verbs that appear on the screen, by performing the corresponding action verb.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Memorization of the verbs by imagining the action
Description: The participant reads aloud the verbs that appear on the screen, by imagining the corresponding action verb.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memorization of the verbs by imagining the action
Description: The participant reads aloud the verbs that appear on the screen, by imagining the corresponding action verb.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Memorization of the action verbs by means of another word
Description: The participant reads aloud the verbs that appear on the screen. Then, he reads, without memorizing it, a word associated with the action verb to be learnt to favor the memorization of that one. The word is written near the action verb.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memorization of the action verbs by means of another word
Description: The participant reads aloud the verbs that appear on the screen. Then, he reads, without memorizing it, a word associated with the action verb to be learnt to favor the memorization of that one. The word is written near the action verb.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simple memorization of the verbs
Description: The participant reads aloud the verbs that appear on the screen, without additional instructions (control condition).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simple memorization of the verbs
Description: The participant reads aloud the verbs that appear on the screen, without additional instructions (control condition).
Study: NCT02464566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Education
Study: NCT01932840

Intervention type: BEHAVIORAL
Intervention: Mock package questionnaire
Description: Within a online questionnaire we exposed participants randomly to 4 mock margarine packages differing only by the claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
Study: NCT00117949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
Study: NCT02636816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbetocin
Description: drug used to increase the tone of uterine muscle to prevent post partum hemorrhage after cesarean delivery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbetocin
Description: drug used to increase the tone of uterine muscle to prevent post partum hemorrhage after cesarean delivery.
Study: NCT04260503

Intervention type: OTHER
Intervention: Monitoring of the gut-microbiome and ultrasound elasticity.
Description: The investigator will investigate the alteration of gut-microbiome and liver stiffness by restoration of bile flow by operation.

Intervention type: OTHER
Intervention: Monitoring of the gut-microbiome
Description: The investigator will investigate the alteration of gut-microbiome before and after operation.

Intervention type: OTHER
Intervention: Monitoring of the gut-microbiome
Description: The investigator will investigate the alteration of gut-microbiome along with the disease progress.

Intervention type: OTHER
Intervention: Monitoring of the gut-microbiome.
Description: The investigator will investigate the alteration of gut-microbiome according to the normal development.
Study: NCT03221374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: 8-week mindfulness based stress reduction course intended to develop mind-body awareness through mindfulness practices.
Study: NCT03048162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride
Description: 500 ml of 0.9% isotonic sodium chloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethylstarch
Description: 500 ml of 6% Hydroxyethylstarch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer-Lactate Infusion Solution Bag
Description: 500 ml of Ringer-Lactate Infusion Solution Bag
Study: NCT04090892

Intervention type: PROCEDURE
Intervention: selective percutaneous muscle release
Description: Children will be evaluated before and two times after they undergo a selective percutaneous myofascial release. Investigators make no determination about the need for the surgery or which muscles are released, nor do they participate in the surgery. The investigators are assess outcomes on gait and motor function.
Study: NCT01973049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Ribavirin
Study: NCT02567968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg). The time to wake will be measured.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Anesthetized volunteers will be allowed to wake after injection of saline (placebo control). The time to wake will be measured.
Study: NCT02016170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180mg
Description: After providing written informed consent, eligible patients on maintenance prasugrel meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily maintenance dose for 7±2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel 10mg
Description: After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days
Study: NCT00582400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Trisenox will be diluted with 100 to 250 mL 0.9% Sodium Chloride injection, USP, using proper aseptic technique, immediately after withdrawal from the ampule. The Trisenox ampule is single-use and does not contain any preservatives. Unused portions of each ampule should be discarded properly. Trisenox is not to be mixed with other medications.~The loading dose of Trisenox will be administered intravenously over 2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. The drug will be administered IV through a functional peripheral or central venous line. Trisenox is not a vesicant, and may be a mild irritant if administered into the skin without dilution.
Study: NCT03660839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artefenomel (OZ439)
Description: Pharmaceutical form: Granules for oral suspension Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artefenomel (OZ439)
Description: Pharmaceutical form: Granules for oral suspension Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artefenomel (OZ439)
Description: Pharmaceutical form: Granules for oral suspension Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferroquine (SSR97193)
Description: Pharmaceutical form: Capsule Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferroquine (SSR97193)
Description: Pharmaceutical form: Capsule Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferroquine (SSR97193)
Description: Pharmaceutical form: Capsule Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferroquine (SSR97193)
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study: NCT02979353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shed-Meds: A Patient-Centered Deprescribing Intervention
Description: The goal of the intervention is to safely deprescribe medications, as defined by dose reductions and stopped medications, based on a combination of clinical criteria and patient preferences.
Study: NCT04014322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette
Description: All participants will be provided with 8 weeks of e-cigarettes at no cost based on self-report of regular cigarette use.~All participants will receive a total of 8-10 remote counseling sessions (via phone or video conference) and during which they will discuss ways to switch from smoking cigarettes to exclusively using e-cigarettes, barriers and strategies to overcome them. (All participants will receive sessions at baseline, 2 days, 7 days, 2 weeks, 3 weeks, and 4 weeks, 6 weeks , and 8 weeks after the baseline assessment. Two additional sessions at 5 weeks and 7 weeks (after the baseline assessment) will be provided to those who are still smoking combustible cigarettes at 4-week assessment.)
Study: NCT00208286

Intervention type: DEVICE
Group type: OTHER
Intervention: PFC Sigma Fixed Bearing
Description: PFC Sigma Fixed Bearing system for use in total knee arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFC Sigma Mobile Bearing
Description: PFC Sigma Mobile Bearing system for use in total knee arthroplasty
Study: NCT01395186

Intervention type: PROCEDURE
Group type: OTHER
Intervention: varicocelectomy
Description: varicocelectomy for painful varicocele
Study: NCT02161965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: 20mg or 15mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluindione

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study: NCT01582607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine plain
Description: 2.0 mL (10mg) plain bupivacaine hydrochloride 0.5% intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine plain
Description: 2.0 ml (15mg) plain ropivacaine 0.75% intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine plain
Description: 2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5% intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine plain +fentanyl
Description: 2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine plain +. fentanyl
Description: 2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine plain +fentanyl
Description: 2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
Study: NCT03505853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givosiran
Description: single dose of givosiran by subcutaneous (sc) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-probe cocktail
Description: includes midazolam, caffeine, losartan, omeprazole, and dextromethorphan
Study: NCT00718679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVN201
Description: Intralymphativ injection of the study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01856088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiron Stent
Description: stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biomatrix Flex Stent
Description: stent implantation
Study: NCT03441581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eluxadoline
Description: Eluxadoline 100 mg oral tablets BID with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eluxadoline
Description: Eluxadoline 100 mg oral tablets BID with food.
Study: NCT03416764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EFP-NF training
Description: Experimental groups (among participants with and without steady menstrual cycle) will receive a total of 10 training sessions during 10 weeks. In addition to EFP-NF training, participants in the experimental groups will continue to be treated as usual at Clinic for Sexual Assault.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EFP-NF training
Description: Experimental groups (among participants with and without steady menstrual cycle) will receive a total of 10 training sessions during 10 weeks. In addition to EFP-NF training, participants in the experimental groups will continue to be treated as usual at Clinic for Sexual Assault.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EFP-NF training
Description: Experimental groups (among participants with and without steady menstrual cycle) will receive a total of 10 training sessions during 10 weeks. In addition to EFP-NF training, participants in the experimental groups will continue to be treated as usual at Clinic for Sexual Assault.
Study: NCT02115906

Intervention type: OTHER
Intervention: 1H/31P Magnetic Resonance Spectroscopy
Description: The 31P-MRS examinations will be performed in a 7 T MR system (Siemens Healthcare, Erlangen, Germany) using a double-tuned (31P/1H) surface coil (Rapid Biomedical Ltd, Rimpar, Germany), with a diameter of 10 cm. Participants will be investigated lying in lateral position with the right lobe of the liver positioned over the coil.

Intervention type: OTHER
Intervention: 1H/31P Magnetic Resonance Spectroscopy
Description: The 31P-MRS examinations will be performed in a 7 T MR system (Siemens Healthcare, Erlangen, Germany) using a double-tuned (31P/1H) surface coil (Rapid Biomedical Ltd, Rimpar, Germany), with a diameter of 10 cm. Participants will be investigated lying in lateral position with the right lobe of the liver positioned over the coil.

Intervention type: OTHER
Intervention: oral glucose tolerance testing
Description: In patients without overt diabetes, glucose tolerance will be assessed by an oral glucose tolerance test, routinely performed at the outpatients clinic. The test will be performed in the morning after an overnight fast of at least 8 hours. Blood will be drawn via a catheter placed in an antecubital vein of one arm. Blood samples for the assessment of glucose, insulin, C-peptide, free fatty acids and growth hormone will be drawn at baseline as well as 30, 60, 90 and 120 minutes after ingestion of 75g glucose in a solution.~Concentrations of glucose, insulin and C-peptide will be used to derive parameters of insulin secretion and insulin sensitivity by mathematical modelling.

Intervention type: OTHER
Intervention: oral glucose tolerance testing
Description: In patients without overt diabetes, glucose tolerance will be assessed by an oral glucose tolerance test, routinely performed at the outpatients clinic. The test will be performed in the morning after an overnight fast of at least 8 hours. Blood will be drawn via a catheter placed in an antecubital vein of one arm. Blood samples for the assessment of glucose, insulin, C-peptide, free fatty acids and growth hormone will be drawn at baseline as well as 30, 60, 90 and 120 minutes after ingestion of 75g glucose in a solution.~Concentrations of glucose, insulin and C-peptide will be used to derive parameters of insulin secretion and insulin sensitivity by mathematical modelling.

Intervention type: OTHER
Intervention: Thyroid sonography
Description: In acromegalic patients thyroid morphology will be assessed at the outpatient clinic of the Division of Endocrinology and Metabolism, using standard ultrasound technique. Measurements will be performed by a well- experienced physician at baseline and at each follow up examination in an out-patient care setting.
Study: NCT03311646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal nicotine content cigarettes (NNC, Baseline)
Description: Participants will exclusively smoke research cigarettes that have a normal nicotine content for five days/four nights while staying in a hotel.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC)
Description: Participants will exclusively smoke research cigarettes that have a very low nicotine content for five days/four nights while staying in a hotel.